AAA
ACRS icon

Affinity Asset Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Affinity Asset Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-129,100
Closed -$1.04M – 71
2023
Q1 		$1.04M Buy
+129,100
New +$1.64M 0.34% 55

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Affinity Asset Advisors's ACRS Position: Q4 2022 in Review

Affinity Asset Advisors sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 136,434 shares — an estimated $2.15M sold.

Affinity Asset Advisors first reported a position in ACRS in Q1 2021 and held it in 7 quarters. The position peaked at $6.3M in Q3 2021. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

  • Affinity Asset Advisors reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Affinity Asset Advisors sold 136,434 Aclaris Therapeutics shares in Q4 2022, an estimated $2.15M.
  • Affinity Asset Advisors first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 7 quarters.
  • Affinity Asset Advisors's Aclaris Therapeutics position peaked at $6.3M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.